Midlife blood pressure change and left ventricular mass and remodelling in older age in the 1946 British birth cohort study†

Arjun K. Ghosh1,2*, Rebecca J. Hardy2, Darrel P. Francis1, Nishi Chaturvedi4, Denis Pellerin3, John Deanfield4, Diana Kuh2, Jamil Mayet1, and Alun D. Hughes4, On behalf of the Medical Research Council National Survey of Health and Development (NHSD) Scientific and Data Collection Team

1International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London, 59–61 North Wharf Road, London W2 1LA, UK; 2Medical Research Council Unit for Lifelong Health and Ageing, University College London, London, UK; 3The Heart Hospital, University College London, London, UK; and 4Institute of Cardiovascular Science, University College London, London, UK

Received 18 March 2014; revised 18 August 2014; accepted 28 August 2014; online publish-ahead-of-print 22 September 2014

See page 3242 for the editorial comment on this article (doi:10.1093/eurheartj/ehu371)

Aims Antecedent blood pressure (BP) may contribute to cardiovascular disease (CVD) independent of current BP. Blood pressure is associated with left ventricular mass index (LVMI) which independently predicts CVD. We investigated the relationship between midlife BP from age 36 to 64 and LVMI at 60–64 years.

Methods and results A total of 1653 participants in the British 1946 Birth Cohort underwent BP measurement and echocardiography aged 60–64. Blood pressure had previously been measured at 36, 43, and 53 years. We investigated associations between BP at each age and rate of change in systolic blood pressure (SBP) between 36–43, 43–53, and 53–60/64 years on LVMI at 60–64 years. Blood pressure from 36 years was positively associated with LVMI. Association with SBP at 53 years was independent of SBP at 60–64 years and other potential confounders (fully adjusted $\beta$ at 53 years = 0.19 g/m²; 95% CI: 0.11, 0.27; $P$ = 0.001). Faster rates of increase in SBP from 43 to 53 years and 53 to 60/64 years were associated with increased LVMI. Similar relationships were seen for diastolic, pulse, and mean pressure. Rate of increase in SBP between 43–53 years was associated with largest change in LVMI ($\beta$ at 43–53 years = 3.12 g/m²; 95% CI: 1.53, 4.72; $P$ < 0.001). People on antihypertensive medication (43 years onwards) had greater LVMI even after adjustment for current BP ($\beta$ at 43 years = 12.36 g/m²; 95% CI: 3.19, 21.53; $P$ = 0.008).

Conclusion Higher BP in midlife and rapid rise of SBP in 5th decade is associated with higher LVMI in later life, independent of current BP. People with treated hypertension have higher LVMI than untreated individuals, even accounting for their higher BP. Our findings emphasize importance of midlife BP as risk factor for future CVD.

Keywords Blood pressure • Left ventricular mass • Left ventricular hypertrophy • Echocardiography

Introduction High blood pressure (BP) is a key risk factor for cardiovascular disease (CVD) and is associated with increased left ventricular (LV) mass (LVM) and left ventricular hypertrophy (LVH) and remodelling. LVM is widely used as a measure of target organ damage in hypertension and increased LVM and LVH are associated with CVD independent of current BP. Exposure to elevated BP over the life course increases the risk of CVD. There is evidence that earlier development of hypertension, 

---

1All authors have contributed to this manuscript and have given permission for its submission for consideration by the European Heart Journal.

*Corresponding author. Tel: +44 20 7670 5700, Fax: +44 20 7580 1501, Email: a.ghosh@imperial.ac.uk

© The Author 2014. Published by Oxford University Press on behalf of the European Society of Cardiology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
elevated BP in early adulthood or antecedent elevated BP confer increased risk. This might reflect the relative stability (tracking) of BP across life; the cumulative burden of lifetime exposure to high BP; or vulnerability to the effects of high BP at particular periods in the life course, i.e. sensitive periods. The extent to which the influence of long-term elevated BP can be reversed by treatment or the extent to which long-term treatment prevents increases in LVM has been little studied outside the context of clinical trials, although several trials have demonstrated that antihypertensive treatment (HTT) causes regression of LVM in the short term.

We studied the nationally representative 1946 British birth cohort [the Medical Research Council National Survey of Health and Development (MRC NSHD)], to determine the relationship between longitudinal changes in BP over a 28-year period (aged 36 to 60–64) and LVM at age 60–64 years and also assessed the impact of HTT in the same individuals over the same period.

**Methods**

**Participants**

The MRC NSHD is a prospective birth cohort study of singleton births that occurred in 1 week of March 1946 in England, Scotland, and Wales (5362 births; 2547 women, 2815 men). The parents of the cohort members were married with equal numbers of fathers engaged in manual and non-manual work. Follow-up included over 20 contacts with the whole cohort between birth and the most recent data collection when the participants were between 60 and 64 years of age. The study complies with the Declaration of Helsinki, the research protocol was approved by the local ethics committee and all participants gave informed consent.

Survey members had been interviewed in their own homes by trained research nurses at ages 36, 43, and 53 years. Between October 2006 and February 2011 (at 60–64 years), 2856 eligible study members (those known to be alive and with a known address in England, Scotland, or Wales) were invited to complete a postal questionnaire and attend an examination (n ¼ 570), had previously withdrawn from the study (n ¼ 594), or had been lost to follow-up (n ¼ 564). Those who declined the clinic visit were offered a home examination by a trained nurse. Of those invited, 2229 (78%) responded: 1690 (59.1%) attended a CRF and 539 (18.9%) were offered a home examination by a trained nurse. Of those invited, (n ¼ 564). Those who declined the clinic visit were offered a home examination by a trained nurse. Of those invited, 2229 (78%) responded: 1690 (59.1%) attended a CRF and 539 (18.9%) had a home visit.

**Clinic assessment**

Height and weight were measured at the CRF and body mass index (BMI) calculated. Sitting brachial BP was measured in the upper right arm as the average of two measures with an appropriately sized cuff after 5 min of rest. At 36 and 43 years a Hawksley Random Zero sphygmomanometer was used and an Omron HEM-705 was used at 53 and 60–64 years. Measurements from the Random Zero sphygmomanometer were adjusted using published conversion equations to achieve compatibility with later measurements. Mean arterial pressure (MAP) was calculated as diastolic BP (DBP) + 0.33*pulse pressure (PP). Fasting bloods were also drawn for analysis.

**Echocardiographic studies**

Of the 1690 participants who attended a clinic, 1653 (798 men and 855 women) underwent echocardiography performed by a trained, experienced sonographer according to a strict protocol using GE Vivid I machines and 1480 had analysable images (89%). We carried out sensitivity analyses excluding those with a history of prior myocardial infarction. As there were no significant change on exclusion (Supplementary material online, Table S10), only those with analysable images were excluded from the analyses. Echocardiographic images were obtained from parasternal long axis and short axis, apical 5-, 4-, 3-, 2-chamber and aortic views along with conventional and tissue Doppler in the 4-chamber view. Image optimization was carried out if required using second harmonic imaging. Image analysis was carried out by AKG along with two experienced echocardiographers masked to patient identity using GE EchoPac software (GE Connecticut, USA).

Wall and chamber measures were made in a single core laboratory, LVM was indexed (LVMI) to body surface area (BSA), alternative indexation (height1.7 and height2.7) was also performed to check robustness of findings in the setting of overweight or obesity. Calculation of variables and definition of LVH and LV remodelling was performed according to ASE/EAE guidelines. Quality assurance of echocardiography was performed throughout the study and blind duplicate reading reproducibility studies were carried out on a sample of studies (equal numbers of men and women and with varying image quality) to establish inter- and intrareader variability with excellent reproducibility (intraclass correlation coefficients > 0.8 for all measurements).

**Medication, antihypertensive treatment, and diabetes status**

Medication use was recorded and classified according to the International Classification of Diseases and related Health Problems classification. Type 2 diabetes mellitus (T2DM) was diagnosed based on self-report or clinic blood tests.

**Statistical analysis**

Regression models were used to investigate the association between BP [systolic blood pressure (SBP), DBP, PP, and MAP] at each of the 4 ages at which it was measured and LVM at 60–64 years, routinely with pre-specified covariate adjustment for sex, age at CRF visit and CRF attended. All analyses were carried out with SBP, DBP, PP, or MAP as the respective measure of BP in the model. Interactions between each BP measure and sex were tested, but no significant interactions were found for any of the outcomes presented and data for men and women were pooled. Further multivariable modelling was performed with antihypertensive treatment (HTT), current SBP, BMI, T2DM, smoking status, and physical activity status as covariables. Regression diagnostics were performed, including checks of linearity by examination of residuals and by testing for model improvement on addition of a quadratic term. To investigate whether rate of change at a particular period of midlife was more strongly associated with LVM, we calculated the change in SBP for the periods 36–43 years, 43–53 years, and 53–60/64 years conditional on earlier SBP by modelling each SBP measure (from 43 years onwards) on the earlier measure(s) for each sex and saving the residuals. These residuals reflect mean rate of change in SBP and can be interpreted as the change in SBP above or below that expected on average, given earlier SBP. The residuals were standardized to allow a comparison of the relative strength of associations between periods. We subsequently fitted regression models including all these standardized changes with LVM or relative wall thickness (RWT, a measure of remodelling) as the outcome. The coefficients for each period were compared against each other using Wald tests and models were further adjusted for potential confounders. Relationships with LVH were analysed using multivariable logistic regression. Sensitivity analyses were carried out to assess whether the associations with BP remained unchanged if those on HTT or those who were hypertensive (SBP > 140 mmHg and/or DBP > 90 mmHg) were excluded.
Figure 1 (A) Predicted left ventricular mass index at 60–64 years by systolic blood pressure at 53 years (red) and by systolic blood pressure at 60–64 years (blue) plotted separately for men and women and by antihypertensive treatment status. Vertical lines represent mean systolic blood pressure in the National Survey of Health and Development sample; solid line for men and dashed line for women. (B) Predicted left ventricular mass index at 60–64 years by standard deviation change in systolic blood pressure between 43 and 53 years (magenta) and between 53 and 60–64 years (green) plotted separately for men (solid) and women (dashed), for individuals with an average conditional change in the other periods. Vertical lines represent mean systolic blood pressure change.
Results

Participant characteristics are shown in Table 1. Twenty-four percent of the sample was receiving antihypertensive medication (details of the class of antihypertensive agent used are shown in Supplementary material online, Table S1); 5% of the sample had T2DM; and a normal LV geometry was seen in 43%. Compared with those who attended for echocardiography, those who had home visits had higher BP (138.4/79.3 vs. 135.6/77.3 mmHg), BMI (28.7 vs. 27.6), and a greater prevalence of T2DM (11 vs. 5%) and hypertension (32 vs. 24%).

Associations between left ventricular measures and blood pressure at various ages

Associations between BP and LV outcomes were qualitatively similar for all measures of BP (SBP, DBP, PP, and MAP), so results for SBP are shown below and associations for DBP, PP, and MAP are provided in Supplementary material online, Table S2–S4.

Higher SBP from 36 years onwards was associated with higher LVMI at 60–64 years (Table 2). Associations remained essentially unchanged after adjustment for HTT (Model 2). Systolic blood pressure at 53 years remained independently associated with LVMI with only marginal attenuation in an additional model that was adjusted for SBP at 60–64 years (Model 3), but associations with SBP at 36 years and particularly with SBP at 43 years were weakened. The relationships between LVMI and BP at 53 years and LVMI and HTT at 53 years remained after further adjustment for BMI, presence of T2DM, smoking and physical activity status at 60–64 years. A 10 mmHg higher SBP at 53 years was associated with a 2.2 g/m² higher LVMI after adjustment for age, sex, CRF attended, HTT, and SBP at 60–64 years.

These associations remained when those with hypertension or on HTT were excluded from analyses (Supplementary material online, Table S5 and S6, respectively), although associations with earlier measures of SBP were slightly reduced.

Relationships between BP (both SBP and DBP) and RWT showed a similar pattern to those between BP and LVMI. There was evidence of associations of BP from 43 years onwards with RWT which were independent of BP at 60–64 years (Table 3; Supplementary material online, Table S7).

LHV was also associated with BP from 36 years onwards, although only weakly with BP at 43 years. The association at 53 years was independent of BP at 60–64 years and was unaffected by adjustment for other covariates (for SBP: odds ratio = 1.25, 95% CI = 1.07, 1.45 per 1 SD increase in SBP at 53 years adjusted for age, sex, CRF attended, HTT, SBP at 60–64 years, T2DM, BMI, smoking, and physical activity).

Associations between left ventricular measures and antihypertensive treatment at various ages

Individuals on HTT from 43 years onwards had a higher mean LVMI than those who were not on treatment (Table 2); this difference persisted after adjusting for SBP at 60–64 years and other covariates. For example, individuals receiving HTT at 60–64 years had an LVMI that was 11.2 g/m² greater than those not receiving treatment. Further adjustment for SBP at 60–64 years and other covariates reduced the associations slightly.

We investigated the possibility that the relationship between LVMI and HTT could be explained by people receiving treatment at 60–64 years including a disproportionate number of individuals with high BP at 53 years. However, adjustment for SBP at 53 years only slightly attenuated the effect of HTT on LVMI from 11.2 (95% CI: 7.9, 14.4) g/m² per 1 SD increase in SBP at 53 years to 11.0 (95% CI: 6.7, 15.3) g/m² per 1 SD increase in SBP at 53 years adjusted for age, sex, and CRF attended.

Evidence for a rate-sensitive period in midlife

Faster increases in SBP between 43–53 and 53–60/64 years were significantly related to greater LVMI (Figure 1), whereas increased rate of change in SBP between 36 and 43 years was only weakly related to LVMI. The relationship between rate of change in SBP between 43 and 53 years was significantly stronger than the other two intervals (P = 0.002 for both). After adjustment for HTT, T2DM, BMI, smoking status, and physical activity (Table 4), the associations with change in the latest two periods remained, although the association between change in SBP between 43 and 53 years was somewhat weakened. Estimates were essentially unaltered when further adjusted for prior measures of BMI or changes in BMI (Supplementary material online, Table S8).

Analyses with left ventricular mass indexed to height1.7 or height2.7

All analyses were repeated with LVMI indexed to height1.7 and height2.7. Associations were qualitatively similar to those for LVMI indexed to BSA. The associations between SBP and LVMI at various ages and alternatively indexed LVMI are presented in Supplementary material online, Table S9 and S10.

Discussion

Elevated BP from early midlife predicts higher LVMI, LVH, and LV remodelling in older men and women independent of current BP. We identified 43–53 years as a potential sensitive period when rapid rises in SBP may be particularly detrimental for the development of adverse cardiac structure. We also found that people receiving HTT had higher LVMI, even after accounting for current BP; only some of this effect could be accounted for by prior higher BP.

A few previous studies have investigated the relationship between antecedent high BP in earlier life on subsequent LVMI. Urbina et al.16 reported a significant positive correlation between SBP at baseline in young women but not young men (average age 13 years) and LVMI measured ~4 years later. Toprak et al.17 failed to find a significant relationship between SBP measured at 13 years and LV geometry in adulthood, although high DBP in childhood was associated with subsequent concentric LVH. Dekkers et al.18 found that PP and SBP measured in early adolescence correlated with LVMI measured in African American and European American youths 10 years later; and Ridderstrale et al.19 reported that high BP in a selection of hypertensive male military recruits and controls aged ~20 was predictive of higher LVMI 20 years later. Two other studies have reported that BP in middle age was positively associated with LVMI measured two
Table 1  Characteristics of study participants having at least one echocardiographic measure of interest recorded (n = 1480)

| Variable                                      | N men/women | Value (combined) | Value [men (n = 701)] | Value [women (n = 779)] |
|-----------------------------------------------|-------------|------------------|-----------------------|------------------------|
| Age at echo (years)                           | 701/779     | 63.3 (1.1)       | 63.2 (1.1)            | 63.3 (1.1)             |
| Body mass index (kg/m²)                       | 701/779     | 27.5 (4.6)       | 27.7 (4.0)            | 27.4 (5.1)             |
| Left ventricular internal diameter in diastole (cm) | 701/779   | 4.82 (0.6)      | 5.05 (0.6)            | 4.61 (0.5)             |
| Interventricular septal thickness in diastole (cm) | 701/779    | 1.1 (0.2)       | 1.1 (0.2)             | 1.0 (0.2)              |
| Left ventricular posterior wall thickness in diastole (cm) | 701/779 | 1.0 (0.2)       | 1.0 (0.2)             | 0.9 (0.2)              |
| Left ventricular mass (g)                     | 701/779     | 181.3 (59.3)     | 209.1 (60.4)          | 156.04 (45.7)          |
| Left ventricular mass indexed to BSA (g/m²)   | 701/779     | 95.7 (26.6)      | 104.0 (28.0)          | 88.1 (23.0)            |
| Left ventricular mass indexed to height1.7 (g/m1.7) | 701/779 | 74.3 (22.5)     | 80.6 (23.3)           | 68.3 (20.0)            |
| Left ventricular mass indexed to height2.7 (g/m2.7) | 701/779 | 44.2 (13.2)     | 46.1 (13.7)           | 42.4 (12.6)            |
| Relative wall thickness                        | 701/777     | 0.42 (0.09)      | 0.42 (0.09)           | 0.41 (0.08)            |
| Ejection fraction (%)                          | 700/776     | 68.7 (9.7)       | 67.2 (10.1)           | 69.9 (9.2)             |
| Left ventricular remodelling subtype (normal/concentric remodelling/concentric hypertrophy/eccentric hypertrophy), n (%) | 701/779 | 632 (43)/396 (27)/287 (41)/202 (29) | 74 (5)/46 (6)/27 (5)/15 (5) |
| Systolic blood pressure at 60–64 years (mmHg) | 701/777     | 135.7 (17.9)     | 139.0 (17.7)          | 132.8 (17.7)           |
| Systolic blood pressure at 53 years (mmHg)    | 659/739     | 134.1 (19.1)     | 137.8 (18.9)          | 130.7 (18.7)           |
| Systolic blood pressure at 43 years (mmHg)    | 655/730     | 121.5 (14.5)     | 123.0 (14.3)          | 120.1 (14.6)           |
| Systolic blood pressure at 36 years (mmHg)    | 633/706     | 118.3 (14.0)     | 121.1 (14.2)          | 115.6 (13.4)           |
| Diastolic blood pressure at 60–64 years (mmHg) | 701/777    | 77.4 (9.7)      | 79.0 (9.8)            | 75.9 (9.3)             |
| Diastolic blood pressure at 53 years (mmHg)   | 659/739     | 83.4 (11.9)      | 86.2 (11.9)           | 80.9 (11.3)            |
| Diastolic blood pressure at 43 years (mmHg)   | 655/730     | 78.5 (11.3)      | 80.9 (11.2)           | 76.3 (10.9)            |
| Diastolic blood pressure at 36 years (mmHg)   | 632/706     | 76.0 (11.7)      | 77.8 (11.7)           | 74.4 (11.4)            |
| Heart rate (bpm)                              | 701/777     | 68.5 (11.8)      | 67.2 (12.5)           | 69.7 (11.0)            |
| Total cholesterol (mmol/L)                    | 657/729     | 5.7 (1.2)        | 5.4 (1.1)             | 6.0 (1.2)              |
| High-density lipoprotein cholesterol (mmol/L) | 657/729     | 1.6 (0.4)        | 1.4 (0.3)             | 1.8 (0.4)              |
| Fasting triglycerides (mmol/L)                | 657/729     | 1.1 (0.8)        | 1.2 (0.9)             | 1.0 (0.7)              |
| Fasting glucose (mmol/L)                      | 667/740     | 5.8 (1.2)        | 6.0 (1.2)             | 5.6 (1.2)              |
| Haemoglobin A1C (%)                            | 656/731     | 5.8 (0.7)        | 5.8 (0.7)             | 5.8 (0.6)              |
| Antihypertensive medication, n (%) on antihypertensive medication with controlled BP (< 140/90 mm Hg), n (%) | 620/712 | 315 (24)         | 159 (26)              | 156 (22)               |
| Type 2 DM, n (%)                               | 635/722     | 73 (5)           | 37 (6)                | 36 (5)                 |

Data are mean (SD).  
\(^a\)Median (interquartile range) for skewed variables. 
\(^b\)One individual receiving antihypertensive medication was missing a valid measurement of blood pressure.
### Table 2
Regression between left ventricular mass index at 60–64 years and systolic blood pressure and antihypertensive treatment at four time points with further adjustment for covariates

| Independent variable | Model 1 | Model 2 | Model 3 | Model 4 |
|----------------------|---------|---------|---------|---------|
| β (95% CI) | P | β (95% CI) | P | β (95% CI) | P | β (95% CI) | P |
| Age 36 (n = 1189)   | 0.18 (0.06, 0.29) | 0.001 | 0.19 (0.06, 0.26) | 0.001 | 0.25 (0.11, 0.39) | <0.001 | 0.35 (0.12, 0.61) | <0.001 |
| SBP                   | 0.16 (0.05, 0.23) | 0.001 | 0.25 (0.10, 0.39) | <0.001 | 0.30 (0.15, 0.45) | <0.001 | 0.40 (0.20, 0.61) | <0.001 |
| Age 43 (n = 1230)   | 1.66 (0.77, 2.54) | 0.001 | 1.67 (0.78, 2.55) | 0.001 | 1.72 (0.83, 2.62) | 0.001 | 1.80 (0.91, 2.57) | 0.001 |
| SBP                   | 0.20 (0.10, 0.30) | 0.001 | 0.35 (0.12, 0.57) | <0.001 | 0.45 (0.22, 0.68) | <0.001 | 0.54 (0.31, 0.77) | <0.001 |
| Age 53 (n = 1330)   | 16.72 (7.31, 26.13) | 0.001 | 16.90 (7.55, 26.29) | 0.001 | 17.15 (7.94, 26.34) | 0.001 | 17.39 (8.53, 26.22) | 0.001 |
| SBP                   | 0.09 (0.02, 0.16) | 0.001 | 0.19 (0.04, 0.33) | <0.001 | 0.24 (0.12, 0.36) | <0.001 | 0.30 (0.16, 0.45) | <0.001 |
| Age 60–64 (n = 1428) | 11.59 (8.84, 14.31) | <0.001 | 11.79 (8.84, 14.31) | <0.001 | 11.99 (8.84, 14.31) | <0.001 | 12.19 (8.84, 14.31) | <0.001 |
| SBP                   | 0.11 (0.03, 0.19) | <0.001 | 0.19 (0.04, 0.33) | <0.001 | 0.24 (0.12, 0.36) | <0.001 | 0.30 (0.16, 0.45) | <0.001 |

The variable β regression coefficients for LVMI are: SBP (β = 0.18), HTT (β = 1.66), and T2DM + BMI + smoking status. CI, confidence interval. Model 1: adjusted for age and sex. Model 2: adjusted for age and sex and CRF attended. Model 3: Model 2 + SBP at 60–64 years. Model 4: Model 3 + T2DM + BMI + smoking status + physical activity status. NR, not relevant.

### Notes
1. Regression between left ventricular mass index at 60–64 years and systolic blood pressure and antihypertensive treatment at four time points with further adjustment for covariates.

2. The variable β regression coefficients for LVMI are: SBP (β = 0.18), HTT (β = 1.66), and T2DM + BMI + smoking status. CI, confidence interval. Model 1: adjusted for age and sex. Model 2: adjusted for age and sex and CRF attended. Model 3: Model 2 + SBP at 60–64 years. Model 4: Model 3 + T2DM + BMI + smoking status + physical activity status. NR, not relevant.

3. The majority of these studies did not examine whether the effect of antecedent BP was independent of current BP and therefore the possibility that these observations were simply a consequence of a high correlation between antecedent and current BP (i.e. tracking) could not be excluded. However, a longitudinal analysis of the Framingham offspring study reported that BP in adulthood (mean age 45 years) correlated with the trajectory of LVMI over a subsequent 16 years period.

4. Our findings based on multiple longitudinal measurements of BP extend these earlier studies and show that the effects of antecedent BP in adulthood are not wholly attributable to tracking of BP. Notably, BP at 53 years was more strongly related to LVMI and RWT than BP at 60–64 years and remained significant in a mutually adjusted model suggesting that midlife BP is more influential for LV structure than BP at age 60–64. After adjustment for current BP a 1 SD increase in BP at age 53 years was associated with a 4.2 g/m² higher LVMI, and a 1 SD higher BP at age 53 years was associated with a 25% increased odds of LVH at age 60–64 years. These associations persisted even after multivariable adjustment for other risk factors including BP at age 60–64 years. We further show that a more rapid BP rise between 43–53 years is the strongest correlate of elevated LVMI, with a 1 SD higher rate of rise in BP in this period being associated with a 5.1 g/m² greater LVMI. The increases in LVMI associated with antecedent BP and rate of rise of BP are likely to have prognostic implications: an ~5 g/m² higher LVMI (~0.2 SD of LVMI) can be predicted to correspond to a 7–20% increase in CVD morbidity and mortality on the basis of previous outcome studies. The importance of BP at 53 years as a predictor of LVMI may reflect the relatively rapid acceleration in BP which typically precedes this age. We analysed rate of change in BP over a 28-year period and divided it into temporal segments to establish if there was a ‘sensitive’ period when exposure to elevated BP had a particularly strong influence. Our data suggest that the 5th decade of life (~40–50 years) may be such a period. This is consistent with previous data relating lifetime risk of CVD to BP and BP change in middle age. It is also interesting to note that both elevated BP and an exaggerated rise in midlife have also been reported to be risk factors for dementia two to three decades later, regardless of subsequent BP.

5. Our finding that people with treated hypertension had higher LVMI, even after adjustment for current BP, is in keeping with a previous study showing that LVMI and prevalence of LVH was greater in individuals with well-controlled BP than in normotensive individuals. This led the authors to suggest that effective treatment of hypertension may not achieve complete reversal of cardiac target organ damage. The question of the part played by regression of hypertension may not achieve complete reversal of cardiac target organ damage including interstitial and perivascular fibrosis that may be difficult to reverse even if BP is subsequently well controlled with medication. This provides an additional rationale for on-going therapeutic efforts targeted at reversal of myocardial fibrosis. While elevated LVMI predicts coronary events and cardiac failure, whether the failure to achieve normalization of LVMI implies a subsequent excess of CVD and heart failure remains to be established. Planned future follow-ups of the British MRC NSHD cohort will provide important information on this question.
Table 3  Regression between relative wall thickness at 60–64 years and systolic blood pressure and antihypertensive treatment at four time points with further adjustment for covariables

| Independent variable | Model 1 | Model 2 | Model 3 | Model 4 |
|----------------------|---------|---------|---------|---------|
|                      | $\beta$ (95% CI) $\times 10^3$ | $P$ | $\beta$ (95% CI) $\times 10^3$ | $P$ | $\beta$ (95% CI) $\times 10^3$ | $P$ | $\beta$ (95% CI) $\times 10^3$ | $P$ |
| Age 36 (n = 1163) SBP | 0.15 (-0.25, 0.54) | 0.469 | 0.15 (-0.24, 0.54) | 0.455 | 0.03 (-0.37, 0.43) | 0.886 | 0.04 (-0.37, 0.44) | 0.863 |
| Age 43 (n = 1197) SBP | 0.68 (0.32, 1.05) | <0.001 | 0.67 (0.30, 1.04) | <0.001 | 0.57 (0.18, 0.95) | 0.004 | 0.58 (0.20, 0.97) | 0.003 |
| Age 53 (n = 1219) SBP | 0.54 (0.28, 0.79) | <0.001 | 0.51 (0.24, 0.77) | <0.001 | 0.42 (0.14, 0.71) | 0.004 | 0.38 (0.10, 0.67) | 0.009 |
| Age 60–64 (n = 1274) SBP | 0.41 (0.13, 0.68) | 0.004 | 0.38 (0.11, 0.66) | 0.006 | NR | – | 0.32 (0.04, 0.60) | 0.242 |
| Age 36 HTT | -9.05 (-58.14, 40.03) | 0.718 | -10.17 (-59.35, 39.01) | 0.685 | -8.13 (-57.21, 40.95) | 0.745 | -17.31 (-66.23, 31.60) | 0.488 |
| Age 43 HTT | 22.30 (10.61, 55.21) | 0.184 | 18.95 (-13.85, 51.74) | 0.257 | 19.47 (-13.30, 52.25) | 0.244 | 12.17 (-20.64, 44.97) | 0.467 |
| Age 53 HTT | 14.55 (-0.35, 29.45) | 0.056 | 7.97 (-7.24, 23.17) | 0.304 | 8.38 (-6.83, 23.59) | 0.280 | 4.01 (-11.44, 19.46) | 0.611 |
| Age 60–64 HTT | 14.51 (3.21, 25.81) | 0.012 | 13.65 (2.36, 24.94) | 0.018 | NR | – | 6.73 (-4.99, 18.44) | 0.260 |

The variable $\beta$ is regression coefficients for RWT vs. SBP (mmHg) or HTT. CI, confidence interval. Model 1: adjusted for age sex and CRF attended. Model 2: Model 1 + SBP at given age (for HTT). Model 3: Model 2 + SBP at 60–64 years. Model 4: Model 3 + T2DM + BMI + smoking status + physical activity status. NR, not relevant.

Conclusions

Higher BP in midlife and in particular a rapid rate of BP increase in the 5th decade is associated with higher LVMI than untreated individuals; even after accounting for their higher BP. Our findings emphasize the importance of midlife BP as a risk factor for future CVD. However, a previous study by Zureik et al. demonstrated that increased rate of rise in midlife BP cannot be excluded. Nevertheless, a recent round of data collection and hence the possibility of reverse causality, namely that increased LVM in early-life results in raised BP should be considered. Although hypertension have higher LVMI than untreated individuals, even after accounting for their higher BP, our findings emphasize the importance of midlife BP as a risk factor for future CVD.

Current hypertension guidelines do not take into account antihypertensive treatment at four time points with further adjustment for covariables. Participants in the MRC NSHD have previously been found to be representative of the target population. However, a previous study by Zureik et al. demonstrated that increased rate of rise in midlife BP cannot be excluded. Nevertheless, a recent round of data collection and hence the possibility of reverse causality, namely that increased LVM in early-life results in raised BP should be considered. Although hypertension have higher LVMI than untreated individuals, even after accounting for their higher BP, our findings emphasize the importance of midlife BP as a risk factor for future CVD.


### Table 4  Relationship between LVMI at age 60–64 years and rate of change in systolic blood pressure at three time periods (36–43 years), (43–53 years), and (53–60 to 64 years) on LVMI (n = 1085)

| Period of rate of change in systolic blood pressure | Model 1 |  | Model 2 |  |
|----------------------------------------------------|---------|--------|---------|--------|
|                                                    | β (95% CI) | P     | β (95% CI) | P     |
| 36–43 years                                        | 1.38 (0.25, 3.01) | 0.096 | 0.42 (1.20, 2.04) | 0.612 |
| 43–53 years                                        | 5.10 (3.53, 6.67) | <0.001 | 3.12 (1.53, 4.72) | <0.001 |
| 53–60/64 years                                     | 1.62 (0.10, 3.15) | 0.037 | 1.87 (0.35, 3.38) | 0.016 |

The variable β is regression coefficients for LVMI (g/m²) for a 1 SD increase in systolic blood pressure in each interval. CI, confidence interval. Model 1: adjusted for age, sex, and CRF attended. Model 2: Model 1 + T2DM + BMI + smoking status + physical activity status + current HTT.

### Supplementary material
Supplementary material is available at European Heart Journal online.

### Acknowledgements
We thank the MRC Data collection teams for their assistance with this study.

### Funding
This work is supported by Medical Research Council UK, National Institute of Health Sciences Biomedical Research Centre Award to Imperial NHS Healthcare Trust, and The National Institute for Health Research University College London Hospitals Biomedical Research Centre. Funding to pay the Open Access publication charges for this article was provided by the Medical Research Council.

### Conflict of interest
None declared.

### References
1. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancer 2002;360:1903–1913.
2. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990;322:1561–1566.
3. Hammond IW, Devereux RB, Alderman MH, Laragh JH. Relation of blood pressure and body build to left ventricular mass in normotensive and hypertensive employed adults. J Am Coll Cardiol 1988;12:996–1004.
4. Berry JD, Dyer A, Cai X, Garside DB, Ning H, Thomas A, Greenland P, Van Horn L, Tracy RP, Lloyd-Jones DM. Lifetime risks of cardiovascular disease. N Engl J Med 2012;366:321–329.
5. Allen N, Berry JD, Ning H, Van Horn L, Dyer A, Lloyd-Jones DM. Impact of blood pressure and blood pressure change during middle age on the remaining lifetime risk for cardiovascular disease: the cardiovascular lifetime risk pooling project. Circulation 2012;125:37–44.
6. Gray L, Lee IM, Sesso HD, Batty GD. Blood pressure in early adulthood, hypertension in middle age, and future cardiovascular disease mortality: HHAS (Harvard Alumni Health Study). J Am Coll Cardiol 2011;58:2396–2403.
7. Vasan RS, Massaro JM, Wilson PW, Seshadri S, Wolf PA, Levy D, D’Agostino RB. Antecedent blood pressure and risk of cardiovascular disease: the Framingham heart study. Circulation 2002;105:48–53.
8. Klingbeil AJ, Schneider M, Martus P, Messerli FH, Schneider RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003;115:41–46.
9. Wadsworth M, Kuhl D, Richards M, Hardy R. Cohort profile: the 1946 National Birth Cohort (MRC National Survey of Health and Development). Int J Epidemiol 2006;35:49–54.
10. Stang A. Algorithms for converting random-zero to automated oscilometric blood pressure values, and vice versa. Am J Epidemiol 2006;164:85–94.
11. Lang RM, Beier M, Devereux RB, Fischlampf FA, Foster E, Pellicia PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ. Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Working Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005;18:1440–1462.
12. Chirinos JA, Segers P, De Buyzere ML, Kromnal RA, Raja MW, De Bacquer D, Claessens T, Gillebert TC, St John-Sutton M, Rietzschel ER. Left ventricular mass: allometric scaling, normative values, effect of obesity, and prognostic performance. Hypertension 2010;56:91–98.
13. de Simone G, Daniels SR, Devereux RB, Meyer RA, Roman MJ, de Divitis O, Alderman MH. Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and impact of overweight. J Am Coll Cardiol 1992;20:1251–1260.
14. Kuhl D, Pierce M, Adams J, Dearfield J, Ekeland U, Friberg P, Ghosh AK, Harwood N, Hughes A, Macfarlane P, Misha G, Pellerin D, Wong A, Stephen AM, Richards M, Hardy R. Cohort profile: updating the cohort profile for the MRC National Survey of Health and Development: a new clinic-based data collection for ageing research. Int J Epidemiol 2011;40:e1–e9.
15. Mishra G, Nitsch D, Black S, De SB, Kuhl D, Hardy R. A structured approach to modelling the effects of binary exposure variables over the life course. Int J Epidemiol 2009;38:528–537.
16. Urbina EM, Gidding SS, Bao W, Pickoff AS, Berdusui K, Berenson GS. Effect of body size, ponderosity, and blood pressure on left ventricular growth in children and young adults in the Bogalusa Heart Study. Circulation 1995;91:2400–2406.
17. Toparak A, Wang H, Chen W, Paul T, Srinivasan S, Berenson G. Relation of childhood risk factors to left ventricular hypertrophy (eccentric or concentric) in relatively young adulthood (from the Bogalusa Heart Study). Am J Cardiol 2006;101:1621–1625.
18. Dekkers C, Treiber FA, Kapuku G, van Den Oord Ej, Snieder H. Growth of left ventricular mass in African American and European American youth. Hypertension 2002;39:943–951.
19. Riddende W, Salovee O, Johannson MC, Bergman A, Jern S, Hrafniksdottor TJ. Consistency of blood pressure and impact on cardiovascular structure over 25 years in young men. J Intern Med 2010;267:295–304.
20. Strand AH, Gudmundsdottor H, Os I, Smith G, Westheim AS, Bjorneheim R, Kjeldsen SE. Arterial plasma noreadrenaline predicts left ventricular mass independent of blood pressure and body build in men who develop hypertension over 20 years. J Hypertens 2006;24:905–913.
21. Sundström J, Lind L, Arén J, Zethelius B, Andren B, Lithell HO. Echocardiographic and electrocardiographic diagnoses of left ventricular hypertrophy predict mortality independently of each other in a population of elderly men. Circulation 2001;103:2346–2351.
22. Lieb W, Xanthakis V, Sullivan LM, Aragam J, Pencina MJ, Larson MG, Benjamin EJ, Vasan RS. Longitudinal tracking of left ventricular mass over the adult life course: clinical correlates of short- and long-term change in the Framingham offspring study. Circulation 2009;119:3085–3092.
23. Armstrong AG, Gidding S, Gjesdal O, Wu C, Bluemke DA, Lima JA. LV mass assessed by echocardiography and CMR, cardiovascular outcomes, and medical practice. JACC Cardiovasc Imaging 2012;5:839–848.
24. Armstrong AG, Jacobs DR Jr, Gidding S, Gjesdal O, Wu C, Bluemke DA, Lima JA. LV mass assessed by echocardiography and CMR, cardiovascular outcomes, and medical practice. JACC Cardiovasc Imaging 2012;5:839–848.
26. Joas E, Backman K, Gustafson D, Ostling S, Waern M, Guo X, Skoog I. Blood pressure trajectories from midlife to late life in relation to dementia in women followed for 37 years. Hypertension 2012;59:796–801.

27. Launer LJ, Hughes T, Yu B, Masaki K, Petrovitch H, Ross GW, White LR. Lowering midlife levels of systolic blood pressure as a public health strategy to reduce late-life dementia: perspective from the Honolulu Heart Program/Honolulu Asia Aging Study. Hypertension 2010;55:1352–1359.

28. Mancia G, Carugo S, Grassi G, Lanzarotti A, Schiavina R, Cesana G, Sega R. Prevalence of left ventricular hypertrophy in hypertensive patients without and with blood pressure control: data from the PAMELA population. Pressioni Arteriose Monitorate E Loro Associazioni. Hypertension 2002;39:744–749.

29. Frohlich ED. Left ventricular hypertrophy: a “factor of risk”: mass is reversible, but is the risk? J Am Coll Cardiol 2004;43:2216–2218.

30. Gaasch WH, Zile MR. Left ventricular diastolic dysfunction and diastolic heart failure. Annu Rev Med 2004;55:373–394.

31. Leask A. Potential therapeutic targets for cardiac fibrosis: TGFbeta, angiotensin, endothelin, CCN2, and PDGF, partners in fibroblast activation. Circ Res 2010;106:1675–1680.

32. Mancia G, Laurent S, gabiti-Rosei E, Ambrosioni E, Burnier-M, Caulfield MJ, Cifkova R, Clement D, Coca A, Dominiczak A, Erdine S, Fagard R, Farsang C, Grassi G, Haller H, Heagerty A, Kjeldsen SE, Kioiowski W, Mallion JM, Manolis A, Narkiewicz K, Nilsson P, Olsen MH, Rahn KH, Redon J, Rodicio J, Ruilope L, Schnieder RE, Struijker-Boudier HA, Van Zwieten PA, Vigiimaa M, Zanchetti A. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009;27:2121–2158.

33. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedebe O, Smith SC Jr, Svetkey LP, Taler SJ, Townsend RR, Wright JT Jr, Narva AS, Ortiz E. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014;311:507–520.

34. Skov K, Julius S, Nesbitt S, Mulvany MJ. Can hypertension be prevented? The Danish Hypertension Prevention Project and the Trial of Prevention of Hypertension studies. Curr Opin Cardiol 2002;17:380–384.

35. Julius S, Nesbitt SD, Egan BM, Weber MA, Michelson EL, Kaciroti N, Black HR, Grimm RH Jr, Messerli FH, Oparil S, Schork MA. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 2006;354:1685–1697.

36. Pierce MB, Silverwood RJ, Nitsch D, Adams JE, Stephen AM, Nip W, Macfarlane P, Wang A, Richards M, Hardy R, Kuh D, Scientific N, Data Collection T. Clinical disorders in a post war British cohort reaching retirement: evidence from the First National Birth Cohort study. PLoS ONE 2012;7:e44857.

37. Zureik M, Bonithon-Kopp C, Diebold B, Ducimetiere P, Guize L. Combined effects of blood pressure and body mass index on left ventricular structure in middle-aged males: cross-sectional and 2-year longitudinal results. J Hypertens 1995;13:979–985.

Midlife blood pressure and future cardiac mass 3295